Champions Oncology Stock Filter Stocks by Fundamentals
| CSBR Stock | USD 8.01 0.35 4.19% |
Fundamental analysis of Champions Oncology allows traders to better anticipate movements in Champions Oncology's stock price by examining its financial health and performance throughout various phases of its business cycle.
Champions | Shares Owned by Insiders | Build AI portfolio with Champions Stock |
Champions Oncology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Champions Oncology from analyzing Champions Oncology's financial statements. These drivers represent accounts that assess Champions Oncology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Champions Oncology's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 141.0M | 101.4M | 65.8M | 65.7M | 59.1M | 46.0M | |
| Enterprise Value | 145.9M | 101.8M | 64.3M | 70.5M | 63.5M | 44.4M |
Champions Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Champions Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Champions Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Champions Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Champions Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Champions Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Champions Oncology's value.| Shares | Northern Trust Corp | 2025-03-31 | 54 K | Acadian Asset Management Llc | 2025-03-31 | 39.5 K | Hightower Advisors, Llc | 2025-03-31 | 35.2 K | Bank Of New York Mellon Corp | 2025-03-31 | 26.7 K | State Street Corp | 2025-03-31 | 26.2 K | Hillsdale Investment Management Inc. | 2025-03-31 | 26.1 K | Bank Of America Corp | 2025-03-31 | 25.3 K | Goldman Sachs Group Inc | 2025-03-31 | 23.1 K | Jane Street Group Llc | 2025-03-31 | 23 K | Battery Management Corp | 2025-03-31 | 2.4 M | Nea Management Company, Llc | 2025-03-31 | 1.7 M |
Champions Fundamentals
| Return On Equity | 0.38 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 113.99 M | ||||
| Shares Outstanding | 13.83 M | ||||
| Shares Owned By Insiders | 25.85 % | ||||
| Shares Owned By Institutions | 49.30 % | ||||
| Number Of Shares Shorted | 109.22 K | ||||
| Price To Earning | 220.00 X | ||||
| Price To Book | 20.25 X | ||||
| Price To Sales | 1.89 X | ||||
| Revenue | 50.16 M | ||||
| Gross Profit | 30.22 M | ||||
| EBITDA | (5.05 M) | ||||
| Net Income | (7.28 M) | ||||
| Cash And Equivalents | 8.06 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 7.43 M | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 1.11 X | ||||
| Book Value Per Share | 0.40 X | ||||
| Cash Flow From Operations | (6.14 M) | ||||
| Short Ratio | 2.94 X | ||||
| Earnings Per Share | 0.45 X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 210 | ||||
| Beta | 0.37 | ||||
| Market Capitalization | 110.75 M | ||||
| Total Asset | 26.13 M | ||||
| Retained Earnings | (84.59 M) | ||||
| Working Capital | (7.9 M) | ||||
| Current Asset | 4.34 M | ||||
| Current Liabilities | 5.31 M | ||||
| Net Asset | 26.13 M |
About Champions Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Champions Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Champions Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Champions Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Champions Stock
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.